THERAPY DOSSIER · th-ca99216f74a3

LMN-NKA ([Lys,MeLeu,Nle]-NKA), neurokinin A and GR 64349

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29237540 ↗2017Reported benefit

Prokinetic effects of neurokinin-2 receptor agonists on the bladder and rectum of rats with acute spinal cord transection.

RatSpinal cord injuryComplete transectionSprague-DawleyFemaleIntravenous, subcutaneous, intramuscular, intranasal and sublingualLMN-NKA 1 to 10 micrograms/kg IV, 10 to 300 micrograms/kg S…Acutely after spinalisation, in anaesthetised rats

Model: Acute spinal cord transection under anaesthesia

All routes produced rapid-onset, short-duration, dose-related increases in bladder pressure and voiding, with onset and duration ranked IV < IN < SC = IM < SL and voiding efficiency around 70 per cent. Vehicle never produced contractions or voiding. Transient hypotension followed intravenous LMN-NK…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…